What is Vertex Pharmaceuticals's indefinite- lived intangible impairment?

Vertex Pharmaceuticals (VRTX) reported indefinite- lived intangible impairment of $470.30M in Q1 2026.

What does indefinite- lived intangible impairment mean?

The total value of identifiable intangible assets like brands or patents before accounting for wear and tear.

Indefinite- lived intangible impairment

Vertex Pharmaceuticals Indefinite- lived intangible impairment remained flat by 0.0% to $470.30M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement

SectionOther

CategoryMarket Position

SignalHigher is better

VolatilityStable

First reportedQ3 2025

Last reportedQ1 2026

How to read this metric

Growth indicates investment in intellectual property, brand equity, or customer relationships.

Detailed definition

The total gross carrying value of identifiable intangible assets, such as brands, customer lists, or software, excluding...

Peer comparison

Common in service-oriented and technology-heavy firms.

Metric ID: other_intangible_assets_gross_excluding_goodwill

Historical Data

2 periods

	Q4 '25	Q1 '26
Value	$470.30M	$470.30M
QoQ Change	—	+0.0%

Range$470.30M – $470.30M

Indefinite- lived intangible impairment at Other Companies

AbbVieABBV View metric

PfizerPFE View metric

Frequently Asked Questions

What is Vertex Pharmaceuticals's indefinite- lived intangible impairment?: Vertex Pharmaceuticals (VRTX) reported indefinite- lived intangible impairment of $470.30M in Q1 2026.
What does indefinite- lived intangible impairment mean?: The total value of identifiable intangible assets like brands or patents before accounting for wear and tear.